Jefferies Financial Group Inc. Sells 39,899 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Jefferies Financial Group Inc. reduced its holdings in Regeneron Pharmaceuticals by 85.8%, selling 39,899 shares and retaining 6,623 shares worth approximately $4.2 million.
• Regeneron reported quarterly earnings of $8.22 per share, missing estimates and reflecting a decline in revenue by 3.7% compared to the previous year.
• The company announced a quarterly dividend of $0.88 per share, translating to an annual yield of 0.6%, with a payout ratio of 8.96%.

Jefferies Financial Group Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 85.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,623 shares of the biopharmaceutical company's stock after selling 39,899 shares during the quarter. Jefferies Financial Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,201,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC boosted its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the period. American Assets Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $427,000. Clearbridge Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 0.7% during the fourth quarter. Clearbridge Investments LLC now owns 3,978 shares of the biopharmaceutical company's stock worth $2,834,000 after purchasing an additional 26 shares during the period. Huntington National Bank grew its position in Regeneron Pharmaceuticals by 51.9% during the fourth quarter. Huntington National Bank now owns 919 shares of the biopharmaceutical company's stock valued at $655,000 after purchasing an additional 314 shares in the last quarter. Finally, Thoroughbred Financial Services LLC increased its stake in Regeneron Pharmaceuticals by 20.8% in the 4th quarter. Thoroughbred Financial Services LLC now owns 592 shares of the biopharmaceutical company's stock valued at $421,000 after buying an additional 102 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 2.3%

Regeneron Pharmaceuticals stock traded up $12.67 on Monday, hitting $571.54. 1,362,515 shares of the stock traded hands, compared to its average volume of 941,817. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a market cap of $61.70 billion, a P/E ratio of 14.40, a price-to-earnings-growth ratio of 2.10 and a beta of 0.33. The company has a current ratio of 5.39, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The business's fifty day simple moving average is $538.05 and its 200 day simple moving average is $602.76.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the firm posted $11.56 earnings per share. The company's quarterly revenue was up 3.6% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on REGN. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Bank of America reduced their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Finally, Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.